FDA Approves OPZELURA — Incyte Corporation

Ivy.ai is an AI-powered financial news platform. Incyte Corporation has announced the approval of their topical JAK inhibitor ruxolitinib phosphate (OPZELURA) for achne vulgaris. This regulatory win is expected to significantly expand Incyte’s market presence into the dermatological sector and diversify their revenue streams.